Patterns, risk factors and management of CD19-directed chimeric antigen receptor T-cell therapy failure in CNS lymphoma
CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) has yielded encouraging efficacy in CNS lymphomas (CNSL), but most patients ultimately experience progressive disease (PD). Risk factors, progression patterns as well as optimal salvage therapies remain unclear.
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
14 January 2026
|
| In: |
Journal of hematology & oncology
Year: 2026, Jahrgang: 19, Heft: 1, Pages: 1-7 |
| ISSN: | 1756-8722 |
| DOI: | 10.1186/s13045-025-01761-8 |
| Online-Zugang: | Resolving-System, kostenfrei, Volltext: https://doi.org/10.1186/s13045-025-01761-8 Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1186/s13045-025-01761-8?utm_source=getftr&utm_medium=getftr&utm_campaign=getftr_pilot&getft_integrator=clarivate |
| Verfasserangaben: | Leon D. Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, Jeremy S. Abramson, Jacob D. Soumerai, Maria Martinez-Lage, J. Erika Haydu, Ganesh M. Shankar, Chirayu Patel, Bryan D. Choi, Jeffrey A. Barnes, Areej El-Jawahri, Ephraim P. Hochberg, P. Connor Johnson, Wolfgang Wick, Marcela V. Maus, Yi-Bin Chen, Matthew J. Frigault and Jorg Dietrich |
| Zusammenfassung: | CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) has yielded encouraging efficacy in CNS lymphomas (CNSL), but most patients ultimately experience progressive disease (PD). Risk factors, progression patterns as well as optimal salvage therapies remain unclear. |
|---|---|
| Beschreibung: | Gesehen am 06.05.2026 |
| Beschreibung: | Online Resource |
| ISSN: | 1756-8722 |
| DOI: | 10.1186/s13045-025-01761-8 |